A considerable body of large-scale placebo-controlled trials in populations with type 2 diabetes are needed to clarify whether SGLT2 inhibitors exhibit beneficial effects in reducing AF/AFL. Here, SLC5A2 is linked to type 2 diabetes mellitus.